Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF -4.53%87 Debt-to-Equity is 0.29 as of May. 2026, which is 41% below its 10-year median of 0.49. GuruFocus rates LOVFF with a GF Score™ of 87/100 and a GF Value™ of $1.23 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 815 Drug Manufacturers companies, Cannara Biotech ranks worse than 51.04% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cannara Biotech's Debt-to-Equity or its related term are showing as below:
LOVFF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28 Med: 0.49 Max: 0.88
Current: 0.29
During the past 8 years, the highest Debt-to-Equity Ratio of Cannara Biotech was 0.88. The lowest was 0.28. And the median was 0.49.
LOVFF's Debt-to-Equity is ranked worse than 51.04% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs LOVFF: 0.29
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cannara Biotech Debt-to-Equity Related Terms
Cannara Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a Debt-to-Equity of 0.29 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannara Biotech and its competitors. This is 41% below median its historical median of 0.49. Over the past decade, Cannara Biotech's Debt-to-Equity has ranged from 0.28 to 0.88. According to the industry distribution chart, Cannara Biotech ranks #416 out of 815 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is Cannara Biotech's Debt-to-Equity too high?
Cannara Biotech's current Debt-to-Equity of 0.29 is 41% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.88. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Cannara Biotech's value of 0.29 is 3.6% above this industry median. Based on the distribution chart, Cannara Biotech ranks #416 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #416 out of 815 companies for Debt-to-Equity. This places Cannara Biotech in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Cannara Biotech's value of 0.29 is 3.6% above this benchmark. Historically, Cannara Biotech's own Debt-to-Equity has ranged from 0.28 to 0.88 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.28, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Debt-to-Equity of 0.29 is 3.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Debt-to-Equity is 0.29, which is 41% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $1.36 — trading 10.6% above its estimated fair value. The current Debt-to-Equity is 0.29, which is 41% below median its 10-year median of 0.49 and 3.6% above the Drug Manufacturers industry median of 0.28. Cannara Biotech's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Debt-to-Equity is 0.29 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.36 is trading 10.6% above its estimated GF Value™ of $1.23.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
Debt-to-Equity: 0.29 (41% below median its 10-year median of 0.49)
GF Value™: $1.23 vs. price of $1.36 (10.6% above fair value)
Industry Position: 3.6% above the Drug Manufacturers median (#416 of 815)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
87GF Score
Get the complete analysis for LOVFF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
